[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Pérez Martínez A, Quintero Calcaño V, González Vicent M, Contra Gómez T, Díaz Pérez MA, Madero López L, Sevilla Navarro J: [High-dose chemotherapy with autologous stem cell rescue in children with high-risk and recurrent brain tumors]. An Pediatr (Barc); 2004 Jul;61(1):8-15
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High-dose chemotherapy with autologous stem cell rescue in children with high-risk and recurrent brain tumors].
  • OBJECTIVES: To improve prognosis in patients with high-risk and recurrent tumors, new therapeutic strategies such as high-dose chemotherapy with autologous stem cell rescue (ASCR) have been developed.
  • Seven patients died of treatment-related toxicities (20 %).
  • The 2-year Kaplan-Meier estimates of event-free survival was 37.64 +/- 8.7 % in all patients, 57 +/- 15 % in the group of patients with high-risk medulloblastoma/supratentorial primitive neuroectodermal tumor (stPNET) and 71.43 +/- 17 % in patients aged less than 4 years with medulloblastoma/stPNET.
  • CONCLUSIONS: In our experience, ASCR may be effective in the treatment of malignant tumors of the central nervous system in patients with controlled disease, in certain histologic groups and chemosensitive tumors (medulloblastoma, malignant astrocytoma), as well as in very young children in whom cranial radiotherapy is contraindicated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Retrospective Studies. Survival Analysis. Transplantation, Autologous

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15228928.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


2. Chi SN, Zimmerman MA, Yao X, Cohen KJ, Burger P, Biegel JA, Rorke-Adams LB, Fisher MJ, Janss A, Mazewski C, Goldman S, Manley PE, Bowers DC, Bendel A, Rubin J, Turner CD, Marcus KJ, Goumnerova L, Ullrich NJ, Kieran MW: Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol; 2009 Jan 20;27(3):385-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor.
  • PURPOSE: Atypical teratoid rhabdoid tumor (ATRT) of the CNS is a highly malignant neoplasm primarily affecting young children, with a historic median survival ranging from 6 to 11 months.
  • PATIENTS AND METHODS: Treatment was divided into five phases: preirradiation, chemoradiation, consolidation, maintenance, and continuation therapy.
  • Intrathecal chemotherapy was administered, alternating intralumbar and intraventricular routes.
  • Radiation therapy (RT) was prescribed, either focal (54 Gy) or craniospinal (36 Gy, plus primary boost), depending on age and extent of disease at diagnosis.
  • Gross total resection of the primary tumor was achieved in 11 patients.
  • Fifteen patients received radiation therapy: 11 focal and four craniospinal.
  • CONCLUSION: This intensive multimodality regimen has resulted in a significant improvement in time to progression and overall survival for patients with this previously poor-prognosis tumor.
  • [MeSH-major] Brain Neoplasms / therapy. Rhabdoid Tumor / therapy. Teratoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Humans. Infratentorial Neoplasms. Prognosis. Prospective Studies. Supratentorial Neoplasms. Young Adult

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):337-42 [12142780.001]
  • [Cites] Pediatr Blood Cancer. 2008 Aug;51(2):235-40 [18381756.001]
  • [Cites] Radiology. 1969 Dec;93(6):1351-9 [4983156.001]
  • [Cites] Hum Pathol. 1987 Apr;18(4):332-7 [3030922.001]
  • [Cites] Pediatr Neurol. 1991 Jul-Aug;7(4):237-42 [1930413.001]
  • [Cites] Med Pediatr Oncol. 1992;20(3):258 [1637409.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):71-5 [7743242.001]
  • [Cites] J Neurooncol. 1995;24(1):21-8 [8523069.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):56-65 [8683283.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1013-9 [9719110.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1083-92 [9737241.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1491-9 [15735125.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):978-86 [15758008.001]
  • [Cites] J Neurooncol. 2005 Mar;72(1):77-84 [15803379.001]
  • [Cites] Pediatr Blood Cancer. 2005 May;44(5):478-86 [15918215.001]
  • [Cites] Neurosurg Focus. 2005 Jun 15;18(6A):E8 [16048294.001]
  • [Cites] J Neurooncol. 2007 Jan;81(1):97-111 [16855864.001]
  • [Cites] J Pediatr Psychol. 2007 Sep;32(8):918-25 [17522113.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):928-40 [17066459.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2877-84 [15254056.001]
  • (PMID = 19064966.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA046274; United States / NCI NIH HHS / CA / R01 CA046274-17A2; United States / NCI NIH HHS / CA / CA46274
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2645855
  •  go-up   go-down


3. Phuphanich S, Baker SD, Grossman SA, Carson KA, Gilbert MR, Fisher JD, Carducci MA: Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neuro Oncol; 2005 Apr;7(2):177-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study.
  • We determined the maximum tolerated dose (MTD), toxicity profile, pharmacokinetic parameters, and preliminary efficacy data of oral sodium phenylbutyrate (PB) in patients with recurrent malignant gliomas.
  • Twenty-three patients with supratentorial recurrent malignant gliomas were enrolled on this dose escalation trial.
  • At 36 g/day, two of four patients developed dose-limiting grade 3 fatigue and somnolence.
  • At the MTD of 27 g/day, one of seven patients developed reversible grade 3 somnolence.
  • Median survival from time of study entry was 5.4 months.
  • The mean value for PB clearance in this patient population was 22 liters/h, which is significantly higher than the 16 liters/h reported in patients with other malignancies who were not receiving P450 enzyme-inducing anticonvulsant drugs (P = 0.038).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2292-300 [11489804.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):984-90 [10071293.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):963-70 [11948101.001]
  • [Cites] J Neurooncol. 2002 Sep;59(3):239-42 [12241121.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2940-9 [12912940.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • [Cites] Cancer Chemother Biol Response Modif. 1990;11:303-20 [2223397.001]
  • [Cites] J Clin Invest. 1993 May;91(5):2288-95 [8486788.001]
  • [Cites] Cancer Res. 1994 Feb 15;54(4):891-5 [8313377.001]
  • [Cites] Int J Cancer. 1995 Feb 8;60(4):507-14 [7829265.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3121-8 [9294475.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(2):118-26 [9654111.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 4;90(21):1621-5 [9811311.001]
  • [Cites] Clin Cancer Res. 1996 Feb;2(2):379-87 [9816181.001]
  • [Cites] Clin Cancer Res. 1997 Oct;3(10):1755-62 [9815560.001]
  • [Cites] Mayo Clin Proc. 1999 Feb;74(2):137-45 [10069350.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3047-55 [11595694.001]
  • (PMID = 15831235.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062475; United States / NCI NIH HHS / CA / U01 CA 62475
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents; 0 / Phenylbutyrates; 9035-51-2 / Cytochrome P-450 Enzyme System
  • [Other-IDs] NLM/ PMC1871887
  •  go-up   go-down


Advertisement
4. Yamamoto M, Oshiro S, Tsugu H, Hirakawa K, Ikeda K, Soma G, Fukushima T: Treatment of recurrent malignant supratentorial astrocytomas with carboplatin and etoposide combined with recombinant mutant human tumor necrosis factor-alpha. Anticancer Res; 2002 Jul-Aug;22(4):2447-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent malignant supratentorial astrocytomas with carboplatin and etoposide combined with recombinant mutant human tumor necrosis factor-alpha.
  • BACKGROUND: This study assesses the safety, tolerance and preliminary efficacy of combined treatment with carboplatin, etoposide and recombinant human mutant tumor necrosis factor-alpha (TNF-SAM2) for recurrent malignant supratentorial astrocytomas at first relapse.
  • Treatment was repeated every 8 to 12 weeks.
  • RESULTS: Ten patients previously treated with surgery, radiation therapy and chemotherapy with a nitrosourea (ranimustine: MCNU) for malignant astrocytomas received this regimen for up to four cycles.
  • Of 9 evaluable patients, three (33%), including one glioblastoma, partially responded to the treatment (PR) with time to tumor progression (TTP) of 231, 121 and 57 weeks, respectively.
  • CONCLUSION: These results suggest that combined therapy with carboplatin, etoposide and recombinant mutant TNF-alpha in this patient population seems to be safe and acceptable and may benefit those with recurrent anaplastic astrocytomas.
  • These intriguing clinical observations warrant a properly stratified randomized trial to determine whether this approach can provide therapeutic benefits and improve survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Supratentorial Neoplasms / drug therapy. Tumor Necrosis Factor-alpha / therapeutic use
  • [MeSH-minor] Adult. Aged. Brain / pathology. Carboplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Patient Selection. Recombinant Proteins / administration & dosage. Treatment Outcome

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12174942.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / Tumor Necrosis Factor-alpha; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


5. Beppu T, Yoshida Y, Arai H, Wada T, Suzuki M, Ogawa A, Hakozaki S, Kubo N: A phase II study of nimustine hydrochloride, cisplatin, and etoposide combination chemotherapy for supratentorial malignant gliomas. J Neurooncol; 2000 Sep;49(3):213-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of nimustine hydrochloride, cisplatin, and etoposide combination chemotherapy for supratentorial malignant gliomas.
  • Twenty-eight patients who were previously treated by aggressive surgery and radiation and were diagnosed with supratentorial malignant gliomas received a combination of nimustine hydrochloride; 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU), cisplatin and etoposide (ACE therapy) as primary treatment.
  • Treatment was repeated at 4-week intervals for up to 3 cycles.
  • The median time of tumor progression was 40 weeks, and the median survival time was 146 weeks.
  • This study demonstrated the effects of ACE combination in patients with supratentorial malignant gliomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cerebellar Neoplasms / drug therapy. Glioma / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Cisplatin / administration & dosage. Dose-Response Relationship, Drug. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Nimustine / administration & dosage. Survival Analysis. Treatment Outcome

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurochir (Wien). 1994;127(1-2):55-9 [7942182.001]
  • [Cites] J Clin Oncol. 1984 May;2(5):432-7 [6726296.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(13):2229-35 [9038603.001]
  • [Cites] Neurosurgery. 1987 Aug;21(2):201-6 [2821446.001]
  • [Cites] Neurol Med Chir (Tokyo). 1993 May;33(5):295-9 [7687035.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1981 May;44(5):397-401 [7021770.001]
  • [Cites] Cancer Treat Rev. 1985 Sep;12 Suppl A:125-36 [3002623.001]
  • [Cites] Cancer Res. 1982 Jun;42(6):2474-9 [6280860.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] J Neurosurg. 1986 Jan;64(1):53-7 [3455717.001]
  • [Cites] Cancer. 1984 Sep 1;54(5):794-9 [6331626.001]
  • [Cites] J Neurosurg. 1989 Jul;71(1):1-9 [2661738.001]
  • [Cites] Cancer Treat Rep. 1976 Nov;60(11):1619-25 [1021234.001]
  • [Cites] J Neurooncol. 1991 Oct;11(2):165-70 [1744684.001]
  • [Cites] Neurol Med Chir (Tokyo). 1996 Aug;36(8):555-8; discussion 558-9 [8831197.001]
  • [Cites] J Neurooncol. 1994;19(3):227-37 [7807173.001]
  • [Cites] J Neurooncol. 1997 Apr;32(2):155-60 [9120545.001]
  • (PMID = 11212900.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0S726V972K / Nimustine; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Sanson M, Napolitano M, Yaya R, Keime-Guibert F, Broët P, Hoang-Xuan K, Delattre JY: Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study. J Neurooncol; 2000 Dec;50(3):245-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study.
  • The objective of the study was to assess the efficacy of docetaxel in recurrent supratentorial malignant gliomas.
  • In the first step 14 patients (age 27-69, median 50; Karnofsky index 50-90, median 75) with recurrent malignant glioma after surgery, radiotherapy and nitrosourea, were enrolled (12 glioblastomas, 2 anaplastic astrocytomas).
  • This study suggests that docetaxel displayed no significant activity in patients with malignant recurrent gliomas.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Paclitaxel / analogs & derivatives. Paclitaxel / therapeutic use. Taxoids
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 1994;33(5):441-4 [7905792.001]
  • [Cites] Cancer Res. 1994 Apr 15;54(8):2207-12 [7909720.001]
  • [Cites] J Clin Oncol. 1997 Dec;15(12):3427-32 [9396393.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3 Suppl 9):1-6 [10426452.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Res. 1991 Sep 15;51(18):4845-52 [1680023.001]
  • [Cites] J Natl Cancer Inst. 1995 Jul 19;87(14):1077-81 [7616600.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2643-55 [7595719.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):2066-71 [7636549.001]
  • [Cites] J Neurooncol. 1999 May;43(1):71-8 [10448874.001]
  • [Cites] J Natl Cancer Inst. 1991 Feb 20;83(4):288-91 [1671606.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2188-94 [9626220.001]
  • [Cites] Invest New Drugs. 1996;14(2):203-6 [8913841.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Aug 31;187(1):164-70 [1381586.001]
  • [Cites] Semin Radiat Oncol. 1999 Apr;9(2 Suppl 1):12-26 [10210536.001]
  • [Cites] J Natl Cancer Inst. 1995 Dec 6;87(23):1804-5 [7473842.001]
  • (PMID = 11263504.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


7. Afra D, Sipos L, Vitanovics D: [Chemotherapy of recurrent supratentorial malignant gliomas (phase II study)]. Ideggyogy Sz; 2002 Jan 20;55(1-2):38-44
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy of recurrent supratentorial malignant gliomas (phase II study)].
  • At the Hungarian National Institute of Neurosurgery 73 recurrent supratentorial malignant tumours were treated by chemotherapy during the last ten years.
  • Chemotherapy was applied after postoperative radiotherapy but in some cases following reoperation only.
  • Forty-three patients received BCNU-DBD (dibromodulcitol) treatment (23 anaplastic astrocytoma--AA, and 20 glioblastoma multiforme--GM): day 1.
  • This course was repeated every six weeks, altogether 2-8 times.
  • Treatment started with vincristine 1.5 mg/sq.m. i.v. (2.0 mg maximum), the next day CCNU 100 mg/sq.m. was given, followed by procarbazine 60 mg/sq.m. on days 8-22. and finished by the same dose of vincristine on day 30.
  • The course was repeated after one month, mostly six times.
  • Chemotherapy of supratentorial malignant glioma recurrences with nitroso-ureas and their combination proved to be efficacious.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Glioblastoma / drug therapy. Supratentorial Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / administration & dosage. Carmustine / administration & dosage. Chemotherapy, Adjuvant. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Mitolactol / administration & dosage. Neoplasm Recurrence, Local. Procarbazine / administration & dosage. Radiotherapy, Adjuvant. Reoperation. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12122942.001).
  • [ISSN] 0019-1442
  • [Journal-full-title] Ideggyógyászati szemle
  • [ISO-abbreviation] Ideggyogy Sz
  • [Language] hun
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; LJ2P1SIK8Y / Mitolactol; U68WG3173Y / Carmustine
  •  go-up   go-down


8. Krampulz T, Hans VH, Oppel F, Dietrich U, Puchner MJ: Long-term relapse-free survival with supratentorial primitive neuroectodermal tumor in an adult: a case report. J Neurooncol; 2006 May;77(3):291-4
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term relapse-free survival with supratentorial primitive neuroectodermal tumor in an adult: a case report.
  • OBJECTIVE: In adults, supratentorial primitive neuroectodermal tumor (sPNET) is a very rare undifferentiated embryoblastic neoplasm.
  • CT- and MRI-scans revealed a right occipital tumor with moderate contrast enhancement.
  • The tumor was completely removed.
  • The original histological diagnosis was that of an undifferentiated sarcoma, malignant hemangioendothelioma, grade III.
  • The patient was treated by CyVADIC chemotherapy and conventional radiation therapy (60 Gy).
  • Microscopy revealed a malignant, highly cellular, poorly differentiated tumor with a desmoplastic component.
  • Up to 20% of tumor nuclei were labeled for Ki-67.
  • Other tumor entities were excluded by immunohistochemistry.
  • The value of chemotherapy is an issue of continuous investigation.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Neuroectodermal Tumors, Primitive / pathology. Sarcoma / pathology. Supratentorial Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Disease-Free Survival. Humans. Ki-67 Antigen / metabolism. Male. Receptor, Nerve Growth Factor / metabolism. Treatment Outcome

  • Genetic Alliance. consumer health - Supratentorial primitive neuroectodermal tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1978 Jan;41(1):56-63 [626943.001]
  • [Cites] Med Pediatr Oncol. 2002 Sep;39(3):190-4 [12210449.001]
  • [Cites] Br J Radiol. 2003 Jan;76(901):62-5 [12595327.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3155-64 [11753995.001]
  • [Cites] Cancer. 1980 Mar 1;45(5):840-4 [7260835.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1027-35 [10694553.001]
  • [Cites] Pediatr Neurosurg. 1998 Oct;29(4):170-7 [9876245.001]
  • [Cites] Med Pediatr Oncol. 2001 Feb;36(2):268-73 [11452934.001]
  • [Cites] J Neurooncol. 1990 Aug;9(1):77-80 [2170592.001]
  • [Cites] Neurosurgery. 2000 Sep;47(3):623-31; discussion 631-2 [10981749.001]
  • [Cites] Acta Oncol. 2003;42(1):55-61 [12665332.001]
  • [Cites] J Neurooncol. 2001 Mar;52(1):57-62 [11451203.001]
  • [Cites] Cancer. 1999 Jul 1;86(1):142-8 [10391574.001]
  • [Cites] Surg Neurol. 1983 Jul;20(1):30-5 [6306852.001]
  • [Cites] Ann Neurol. 1996 Apr;39(4):481-9 [8619526.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):113-20 [12622449.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):905-9 [2033450.001]
  • [Cites] Br J Neurosurg. 1999 Feb;13(1):90-2 [10492697.001]
  • [Cites] Acta Cytol. 2000 Nov-Dec;44(6):1050-8 [11127734.001]
  • [Cites] J Neuropathol Exp Neurol. 1983 Jan;42(1):1-15 [6296325.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):951-7 [7607969.001]
  • [Cites] J Neurooncol. 2002 Oct;60(1):43-52 [12416545.001]
  • [Cites] J Neurooncol. 1998 Feb;36(3):259-67 [9524104.001]
  • [Cites] BMC Cancer. 2004 Jan 26;4:3 [14969593.001]
  • (PMID = 16528456.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Receptor, Nerve Growth Factor
  •  go-up   go-down


9. Sipos L, Vitanovics D, Afra D: [Treatment of recidive malignant gliomas with temozolomide]. Orv Hetil; 2002 May 26;143(21):1201-4
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of recidive malignant gliomas with temozolomide].
  • INTRODUCTION: The prognosis of malignant gliomas despite of the recent advances of diagnostical and therapeutical techniques remains poor.
  • In case of recurrencies reoperation is rarely possible and chemotherapy is the last treatment modality.
  • METHODS: Forty patients with recurrent malignant gliomas had been treated with temozolomide (Temodal).
  • The treatment had to be stopped in four cases.
  • The mean progress free interval was 6.25 and the mean survival time 9 months.
  • According to the primary histology the mean survival time for glioblastoma patients was 6.8 and for anaplastic astrocytoma or mixed oligoastrocytoma patients 12.2 months.
  • CONCLUSIONS: Due to its low toxicity and relatively long survival time after recurrency temozolomide seems to be a promising drug in the treatment of recurrent malignant gliomas.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / therapeutic use. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Supratentorial Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12073541.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


10. Hoving EW, Kros JM, Groninger E, den Dunnen WF: Desmoplastic infantile ganglioglioma with a malignant course. J Neurosurg Pediatr; 2008 Jan;1(1):95-8
Genetic Alliance. consumer health - Ganglioglioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic infantile ganglioglioma with a malignant course.
  • Desmoplastic infantile gangliogliomas (DIGs) are rare supratentorial tumors that arise in infancy.
  • Despite the large size of these lesions, the prognosis is generally considered favorable after gross-total resection (GTR); however, in incidental cases tumor progression has been described.
  • The progressive clinical course was determined by this cell component in spite of GTR and adjuvant chemotherapy.
  • The significance of the presence of a high-grade primitive tumor component in the context of DIG is discussed.
  • [MeSH-major] Ganglioglioma / pathology. Supratentorial Neoplasms / pathology
  • [MeSH-minor] Glial Fibrillary Acidic Protein / metabolism. Humans. Infant. Ki-67 Antigen / metabolism. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local. Neoplasm Staging. Neurosurgical Procedures / methods. Ubiquitin-Protein Ligases / metabolism

  • Genetic Alliance. consumer health - Desmoplastic Infantile Ganglioglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18352812.001).
  • [ISSN] 1933-0707
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


11. Ducray F, Colin P, Cartalat-Carel S, Pelissou-Guyotat I, Mahla K, Audra P, Gaucherand P, Honnorat J, Trouillas P: [Management of malignant gliomas diagnosed during pregnancy]. Rev Neurol (Paris); 2006 Mar;162(3):322-9
Hazardous Substances Data Bank. Fotemustine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of malignant gliomas diagnosed during pregnancy].
  • [Transliterated title] Prise en charge des gliomes malins découverts au cours d'une grossesse.
  • In post-partum additional treatment with chemotherapy was started.
  • In post-partum additional treatment with radiotherapy and chemotherapy was started.
  • Two weeks after surgery the patient's neurological condition worsened and in agreement with the patient a therapeutic abortion was decided.
  • Afterwards additional treatment with radiotherapy and chemotherapy was started.
  • The last patient received combined treatment with radiotherapy and chemotherapy for local recurrence of a mesencephalic high-grade glioma.
  • A posteriori it was discovered that the patient was at 4 months' gestation during this treatment.
  • Their pregnancy should not prevent them from receiving the best treatment for their glioma.
  • Treatment will depend upon clinico-radiological presentation, histology, gestational age and the patient's desires.
  • After the first trimester of gestation this treatment can be given without any important risks for the child.
  • [MeSH-major] Case Management. Glioblastoma / therapy. Pregnancy Complications, Neoplastic / therapy. Supratentorial Neoplasms / therapy
  • [MeSH-minor] Abortion, Therapeutic. Adrenal Cortex Hormones / therapeutic use. Adult. Algorithms. Anesthesia, General. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carbamazepine / therapeutic use. Carmustine / administration & dosage. Cesarean Section. Chemotherapy, Adjuvant. Cranial Irradiation. Craniotomy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Female. Frontal Lobe. Humans. Infant, Newborn. Intracranial Hypertension / etiology. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local. Nitrosourea Compounds / administration & dosage. Nitrosourea Compounds / therapeutic use. Organophosphorus Compounds / administration & dosage. Organophosphorus Compounds / therapeutic use. Paresis / drug therapy. Paresis / etiology. Prednisolone / therapeutic use. Pregnancy. Prenatal Exposure Delayed Effects. Radiotherapy, Adjuvant. Remission Induction. Temporal Lobe

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CARBAMAZEPINE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Rev Neurol (Paris). 2006 Mar;162(3):293-4 [16585883.001]
  • (PMID = 16585887.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antineoplastic Agents; 0 / Nitrosourea Compounds; 0 / Organophosphorus Compounds; 33CM23913M / Carbamazepine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 9PHQ9Y1OLM / Prednisolone; GQ7JL9P5I2 / fotemustine; U68WG3173Y / Carmustine
  •  go-up   go-down


12. Vlassenko AG, Thiessen B, Beattie BJ, Malkin MG, Blasberg RG: Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI. J Neurooncol; 2000;46(3):249-59
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI.
  • Changes in [18F]-2-fluoro-2-deoxyglucose (FDG) uptake and gadopentetate dimeglumine (Gd-DTPA) enhancement before and after the first course of treatment with a cytostatic agent SU101 (N-[(4-trifluoromethyl)-phenyl]-5-methylisoxazole-4-carboxamide, SUGEN) were assessed using positron emission tomography (PET) and magnetic resonance imaging (MRI) in a pilot study of 8 patients with recurrent supratentorial malignant gliomas.
  • The ratios of mean tumor activity to mean contralateral white matter and ipsilateral cerebellar activity were calculated for tumor regions, and SUV values corrected to the subjects' body surface area and glucose level (SUVbsa*glu) were calculated for nontumor regions.
  • Five patients had a substantial increase of tumor volume on both PET and MRI during the first course of SU101.
  • Large tumor volume increases were associated with a short time to clinical progression.
  • The metabolic change in the tumor following the first course of SU101 varied from patient to patient, ranging from a 31% reduction to a 43% increase in FDG uptake ratio.
  • Changes in FDG uptake were not predictive of time to progression or survival.
  • In 2 patients with marked clinical deterioration and rapid tumor growth, there were differences in localization of Gd-DTPA enhancement and FDG hypermetabolism suggesting that hypermetabolism beyond the area of contrast enhancement may be of value in predicting rapid progression of high-grade glioma.
  • SU101 did not induce any appreciable changes in SUVbsa*glu for non-tumor brain in 6 of 8 patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Fluorodeoxyglucose F18. Gadolinium DTPA. Glioblastoma / drug therapy. Isoxazoles / therapeutic use. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / drug therapy. Supratentorial Neoplasms / drug therapy. Tomography, Emission-Computed
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biological Transport, Active / drug effects. Carmustine / administration & dosage. Chemotherapy, Adjuvant. Combined Modality Therapy. Cranial Irradiation. Disease Progression. Disease-Free Survival. Energy Metabolism / drug effects. Female. Glucose / metabolism. Humans. Male. Middle Aged. Platelet-Derived Growth Factor / physiology. Prognosis. Signal Transduction / drug effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. LEFLUNOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 1993 Jan;34(1):12-7 [8418251.001]
  • [Cites] AJR Am J Roentgenol. 1994 Dec;163(6):1459-65 [7992747.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):989-95 [9719107.001]
  • [Cites] Lab Invest. 1992 Oct;67(4):529-34 [1434531.001]
  • [Cites] Radiology. 1990 Jan;174(1):93-8 [2294578.001]
  • [Cites] J Nucl Med. 1994 Jan;35(1):164-7 [8271040.001]
  • [Cites] J Comput Assist Tomogr. 1993 Sep-Oct;17 (5):681-7 [8370819.001]
  • [Cites] J Nucl Med. 1997 May;38(5):692-6 [9170429.001]
  • [Cites] AJNR Am J Neuroradiol. 1993 May-Jun;14 (3):515-23 [8517334.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):57-66 [8384254.001]
  • [Cites] Ann Neurol. 1993 May;33(5):540-8 [8498831.001]
  • [Cites] J Nucl Med. 1986 Feb;27(2):235-8 [3712040.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1995 Feb;58(2):250-2 [7876865.001]
  • [Cites] J Biol Chem. 1999 Jul 2;274(27):19246-53 [10383432.001]
  • [Cites] Biochem Mol Biol Int. 1995 Jul;36(4):835-43 [8528146.001]
  • [Cites] J Nucl Med. 1993 Jan;34(1):1-6 [8418248.001]
  • [Cites] J Neurooncol. 1987;5(3):277-85 [3500281.001]
  • [Cites] J Biol Chem. 1994 Aug 19;269(33):21215-22 [8063742.001]
  • [Cites] Inflamm Res. 1995 Aug;44(8):317-22 [8581517.001]
  • [Cites] Neurology. 1982 Dec;32(12 ):1323-9 [6983044.001]
  • [Cites] Radiology. 1988 Mar;166(3):823-7 [2829270.001]
  • [Cites] J Comput Assist Tomogr. 1993 Jul-Aug;17 (4):509-61 [8392523.001]
  • [Cites] J Comput Assist Tomogr. 1988 Mar-Apr;12 (2):290-7 [3258321.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1077-81 [7862637.001]
  • [Cites] Arch Neurol. 1989 Dec;46(12 ):1302-7 [2556096.001]
  • [Cites] Invest Radiol. 1987 May;22(5):360-71 [3496318.001]
  • [Cites] AJNR Am J Neuroradiol. 1998 Mar;19(3):407-13 [9541290.001]
  • [Cites] Radiology. 1995 Apr;195(1):47-52 [7892494.001]
  • [Cites] Science. 1989 Mar 24;243(4898):1564-70 [2538922.001]
  • [Cites] Biochemistry. 1996 Jan 30;35(4):1270-3 [8573583.001]
  • [Cites] Clin Cancer Res. 1997 Jul;3(7):1167-77 [9815796.001]
  • [Cites] Ann Neurol. 1987 Jan;21(1):59-63 [3493728.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):115-26 [8988735.001]
  • [Cites] AJR Am J Roentgenol. 1988 Jan;150(1):189-97 [3257119.001]
  • [Cites] Klin Wochenschr. 1990 Jan 19;68(2):53-9 [2157088.001]
  • [Cites] Nucl Med Commun. 1989 Nov;10(11):779-90 [2557570.001]
  • [Cites] Cancer. 1994 Nov 15;74(10):2836-42 [7954245.001]
  • [Cites] Cancer. 1988 Sep 15;62(6):1074-8 [3261622.001]
  • [Cites] J Neurosurg. 1985 Jun;62(6):816-22 [2987440.001]
  • (PMID = 10902856.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Isoxazoles; 0 / Platelet-Derived Growth Factor; 0Z5B2CJX4D / Fluorodeoxyglucose F18; G162GK9U4W / leflunomide; IY9XDZ35W2 / Glucose; K2I13DR72L / Gadolinium DTPA; U68WG3173Y / Carmustine
  •  go-up   go-down


13. Jaeckle KA, Hess KR, Yung WK, Greenberg H, Fine H, Schiff D, Pollack IF, Kuhn J, Fink K, Mehta M, Cloughesy T, Nicholas MK, Chang S, Prados M, North American Brain Tumor Consortium: Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol; 2003 Jun 15;21(12):2305-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.
  • PURPOSE: Temozolomide (TMZ) and 13-cis-retinoic acid (cRA) have shown activity in prior single-agent trials of recurrent malignant gliomas (MG).
  • This phase II trial evaluated efficacy and toxicity of combination temozolomide and cRA treatment in recurrent MG.
  • PATIENTS AND METHODS: Adults with recurrent supratentorial MG for whom surgery, radiation, and/or chemotherapy failed were eligible.
  • Treatment included oral TMZ 150 or 200 mg/m2/d, days 1 through 5, and cRA 100 mg/m2/d, days 1 to 21, every 28 days.
  • RESULTS: Eighty-eight eligible patients (glioblastoma multiforme [n = 40]; anaplastic gliomas [n = 48; astrocytoma, 28; oligodendroglioma, 14; mixed glioma, six]) received treatment.
  • Among 499 treatment cycles, the most common grade 3/4 events included granulocytopenia (1.8%), thrombocytopenia (1.4%), and hypertriglyceridemia (1.2%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dacarbazine / analogs & derivatives. Glioma / drug therapy. Supratentorial Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / administration & dosage. Disease Progression. Female. Humans. Isotretinoin / administration & dosage. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12805331.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / CA62399; United States / NCI NIH HHS / CA / CA62412; United States / NCI NIH HHS / CA / CA62422; United States / NCI NIH HHS / CA / CA62426; United States / NCI NIH HHS / CA / CA62455; United States / NCRR NIH HHS / RR / M01-RR00042; United States / NCRR NIH HHS / RR / M01-RR00633; United States / NCRR NIH HHS / RR / M01-RR03186; United States / NCRR NIH HHS / RR / M01-RR0865; United States / NCRR NIH HHS / RR / MO1-RR00056; United States / NCI NIH HHS / CA / UO1CA62399; United States / NCI NIH HHS / CA / UO1CA62405; United States / NCI NIH HHS / CA / UO1CA62407-08; United States / NCI NIH HHS / CA / UO1CA62421
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EH28UP18IF / Isotretinoin
  •  go-up   go-down


14. Sasani M, Oktenoglu T, Ozer AF, Sarioglu AC: Giant supratentorial atypical teratoid/rhabdoid tumor presentation: a case of a five-year-old child with favorable outcome and review of the literature. Pediatr Neurosurg; 2007;43(2):149-54
Genetic Alliance. consumer health - Rhabdoid tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant supratentorial atypical teratoid/rhabdoid tumor presentation: a case of a five-year-old child with favorable outcome and review of the literature.
  • Atypical teratoid/rhabdoid tumor of the central nervous system is a highly malignant neoplasm and that usually arises in the posterior fossa, survival from this is frequently poor.
  • We present a unique case in a 21-month-old girl who had an atypical teratoid/rhabdoid tumor with cystic components located in the right fronto-parietal lobe.
  • The patient underwent radical surgical intervention followed by chemotherapy.
  • Two years later at the last follow-up visit, there was no evidence of a tumor relapse on MRI, and the examination was symptom free.
  • It is possible the favorable outcome of the patient resulted from a rapid diagnosis, prompt management, radical surgical intervention and aggressive chemotherapy.
  • [MeSH-major] Frontal Lobe / surgery. Parietal Lobe / surgery. Rhabdoid Tumor / surgery. Supratentorial Neoplasms / surgery. Teratoma / surgery
  • [MeSH-minor] Actins / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Female. Follow-Up Studies. Glial Fibrillary Acidic Protein / analysis. Humans. Infant. Keratins / analysis. Magnetic Resonance Imaging. Microsurgery. Mitotic Index. Necrosis. Neurologic Examination. Vimentin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 17337931.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Vimentin; 68238-35-7 / Keratins
  • [Number-of-references] 14
  •  go-up   go-down


15. Schmid I, Stachel D, Graubner UB, Elsner R, Schulze S, Pöllinger B, Goetz C, Haas RJ: [Supratentorial primitive neuroectodermal tumor: a single center experience and comparison with the literature]. Klin Padiatr; 2005 May-Jun;217(3):153-7
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Supratentorial primitive neuroectodermal tumor: a single center experience and comparison with the literature].
  • [Transliterated title] Supratentorieller primitiver neuroektodermaler Tumor: Erfahrungen in einem Zentrum im Vergleich zur Literatur.
  • Supratentorial primitive neuroectodermal tumors (stPNETs) are malignant tumors.
  • All had craniospinal irradiation and chemotherapy according to the HIT-91 protocol.
  • The two children with incomplete resection died due to tumor progression after 7 and 10 months.
  • Two of the 4 children with complete tumor resection had local relapses 8 months after diagnosis and died after 14 and 18 months.
  • Despite (high-dose) systemic chemotherapy and intraventricular mafosfamide, he died 21 months after diagnosis due to tumor although remission could be achieved.
  • [MeSH-major] Brain Neoplasms. Cerebellar Nuclei. Corpus Callosum. Frontal Lobe. Neuroectodermal Tumors. Occipital Lobe. Parietal Lobe. Temporal Lobe. Thalamus
  • [MeSH-minor] Brain Stem Neoplasms / secondary. Cerebellar Neoplasms / mortality. Cerebellar Neoplasms / surgery. Child. Child, Preschool. Combined Modality Therapy. Disease Progression. Humans. Male. Mesencephalon. Neoplasm Recurrence, Local. Prognosis. Remission Induction. Time Factors

  • Genetic Alliance. consumer health - Supratentorial primitive neuroectodermal tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15858707.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman JW, Puri RK, Cintredekin Besudotox Intraparenchymal Study Group: Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol; 2007 Mar 1;25(7):837-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.
  • PURPOSE: Glioblastoma multiforme (GBM) is a devastating brain tumor with a median survival of 6 months after recurrence.
  • Convection-enhanced delivery (CED) is a locoregional-administration method leading to high-tissue concentrations with large volume of distributions.
  • We assessed the use of intracerebral CED to deliver CB in patients with recurrent malignant glioma (MG).
  • PATIENTS AND METHODS: Three phase I clinical studies evaluated intracerebral CED of CB along with tumor resection.
  • The main objectives were to assess the tolerability of various concentrations and infusion durations; tissue distribution; and methods for optimizing delivery.
  • All patients underwent tumor resection followed by a single intraparenchymal infusion (in addition to the intraparenchymal one following resection), with a portion of patients who had a preresection intratumoral infusion.
  • The maximum tolerated intraparenchymal concentration was 0.5 microg/mL and tumor necrosis was observed at this concentration.
  • Postoperative catheter placement appears to be important for optimal drug distribution.
  • CB- and procedure-related adverse events were primarily limited to the CNS.
  • CED is a complex delivery method requiring catheter placement via a second procedure to achieve accurate catheter positioning, better drug distribution, and better outcome.
  • [MeSH-major] Drug Delivery Systems / methods. Exotoxins / administration & dosage. Glioma / drug therapy. Immunotoxins / administration & dosage. Interleukin-13 / administration & dosage. Supratentorial Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Catheterization. Convection. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Tissue Distribution

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17327604.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Exotoxins; 0 / IL13-PE38QQR; 0 / Immunotoxins; 0 / Interleukin-13
  •  go-up   go-down


17. Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M, Berger MS, Stokoe D: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst; 2005 Jun 15;97(12):880-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib (also known as Tarceva or OSI-774) has shown promising response rates in malignant gliomas.
  • We investigated the association between expression of EGFR and downstream signaling components and the response of malignant gliomas to erlotinib in a phase I trial of erlotinib administered either alone or with the alkylating agent temozolomide.
  • RESULTS: Of 41 glioma patients, eight responded to treatment.
  • Among six responders with sufficient tumor tissue, none had EGFRvIII mutations.
  • None of the 22 tumors with high levels of phosphorylated PKB/Akt responded to erlotinib treatment, whereas eight of the 18 tumors with low levels of phosphorylated PKB/Akt responded to erlotinib treatment (P < .001).
  • The level of phosphorylated PKB/Akt was also associated with time to progression (P < .001).
  • CONCLUSIONS: Among glioma patients, those with glioblastoma multiforme tumors who have high levels of EGFR expression and low levels of phosphorylated PKB/Akt had better response to erlotinib treatment than those with low levels of EGFR expression and high levels of phosphorylated PKB/Akt.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2005 Jun 15;97(12):868-9 [15956643.001]
  • (PMID = 15956649.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097257; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NINDS NIH HHS / NS / P01 NS42927
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Proto-Oncogene Proteins; 0 / Quinazolines; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.- / Phosphoric Monoester Hydrolases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


18. Agaoglu FY, Ayan I, Dizdar Y, Kebudi R, Gorgun O, Darendeliler E: Ependymal tumors in childhood. Pediatr Blood Cancer; 2005 Sep;45(3):298-303
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Ependymal tumors are classified as ependymoma (benign or low grade) versus anaplastic ependymoma (malignant or high grade).
  • Ependymomas represent 5-10% of intracranial neoplasm in children.
  • In this study, demographic data and the treatment results of pediatric patients with ependymal tumors, treated in a single institute, is reported.
  • The localization was supratentorial in 18, infratentorial in 20, both supra and infratentorial in two patients.
  • Total tumor resection was performed in 20 patients (50%), subtotal in 18 patients (45%), and biopsy only in 2 patients (5%).
  • Postoperative treatment consisted of regional (8 patients) or craniospinal (CSI) (9 patients) radiotherapy (RT) in patients with ependymoma; regional (7 patients) or CSI RT (14 patients) with chemotherapy (ChT) in patients with anaplastic ependymoma; ChT only (1 patient) in patients less than 3 years of age.
  • The standard technique for posterior fossa irradiation was parallel-opposed lateral fields and total dose was 45-54 Gy.
  • Median time for progression or relapse was 24.3 months and there were 19 patients (43.6%) with relapse or progression.
  • CONCLUSIONS: The majority of complete responders were patients who had total tumor removal.
  • Treatment failure occurred mainly within the first 2 years, and outcome was dismal for patients who relapsed or had progressive disease.
  • [MeSH-major] Brain Neoplasms. Ependymoma

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15770637.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Krishnamurthy S, Powers SK, Witmer P, Brown T: Optimal light dose for interstitial photodynamic therapy in treatment for malignant brain tumors. Lasers Surg Med; 2000;27(3):224-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimal light dose for interstitial photodynamic therapy in treatment for malignant brain tumors.
  • BACKGROUND AND OBJECTIVE: The primary goal was to determine the maximal tolerable light dose that can be administered to patients undergoing multifiber interstitial photodynamic therapy (PDT) of malignant brain tumors at a fixed dose of photosensitizer.
  • STUDY DESIGN/MATERIALS AND METHODS: Eighteen patients (12 glioblastomas, 5 anaplastic astrocytoma, and 1 malignant ependymoma) were included in this study.
  • The total light dose delivered to the tumor was divided into three groups of six patients each: 1,500-3,700 J, 3,700-4,400 J, and 4,400-5,900 J.
  • CONCLUSIONS: Increasing the total light dose delivered to the tumor increases the odds of having a permanent neurologic deficit but does not increase survival or time to tumor progression.
  • [MeSH-major] Glioma / drug therapy. Hematoporphyrin Photoradiation / methods. Laser Therapy. Supratentorial Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Dihematoporphyrin Ether / administration & dosage. Disease-Free Survival. Dose-Response Relationship, Radiation. Humans. Middle Aged. Neoplasm Recurrence, Local. Photochemotherapy. Photosensitizing Agents. Stereotaxic Techniques. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 11013384.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


20. Rostomily RC, Halligan J, Geyer R, Stelzer K, Lindsley K, Berger MS: Permanent low-activity (125)I seed placement for the treatment of pediatric brain tumors: preliminary experience. Pediatr Neurosurg; 2001 Apr;34(4):198-205
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Permanent low-activity (125)I seed placement for the treatment of pediatric brain tumors: preliminary experience.
  • Although external beam radiation therapy is effective in the treatment of many pediatric brain neoplasms its use in this patient population has been associated with the development of significant cognitive and endocrine dysfunction and is severely limited as an option in previously irradiated patients.
  • Therefore, we have adopted a strategy for management of residual microscopic disease by implantation of low-activity (125)I seeds in the tumor bed at the time of surgery.
  • Six patients aged 2-14 years with recurrent tumors including two supratentorial primitive neuroectodermal tumors (n = 2), one medulloblastoma, one malignant ependymoma (n = 1), glioblastoma (n = 1) and one pleomorphic xanthoastrocytoma were implanted at the time of reoperation.
  • A total of 11-126 seeds were implanted resulting in total doses of 16-21.8 Gy (after theoretical infinite time) at a depth of 5 mm from the implanted resection bed.
  • Five patients had prior external beam radiation while the other patient (2 years old at initial diagnosis) progressed after surgery and chemotherapy.
  • Two patients had lasting local tumor control.
  • These results suggest that the use of permanent low-activity (125)I seeds as an adjunct to surgery can provide good local tumor control and is a suitable treatment option for pediatric patients.
  • [MeSH-major] Brachytherapy / adverse effects. Brain Neoplasms / radiotherapy. Iodine Radioisotopes / pharmacokinetics. Iodine Radioisotopes / therapeutic use
  • [MeSH-minor] Adolescent. Brain / metabolism. Brain / pathology. Child. Child, Preschool. Drug Implants. Female. Humans. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local. Radiotherapy Dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel
  • (PMID = 11359113.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Grant] United States / PHS HHS / / 2T 32-N07144
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Drug Implants; 0 / Iodine Radioisotopes
  •  go-up   go-down


21. Weber FW, Floeth F, Asher A, Bucholz R, Berger M, Prados M, Chang S, Bruce J, Hall W, Rainov NG, Westphal M, Warnick RE, Rand RW, Rommell F, Pan H, Hingorani VN, Puri RK: Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl; 2003;88:93-103
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma.
  • PURPOSE: This was an open-label, dose-escalation trial of intratumoral administration of IL-4 Pseudomonas Exotoxin (NBI-3001) in patients with recurrent malignant glioma.
  • PATIENTS AND METHODS: A total of 31 patients with histologically verified supratentorial grade 3 and 4 astrocytoma were studied.
  • RESULTS: No drug-related systemic toxicity, as evident by lack of hematological or serum chemical changes, was apparent in any patients; treatment-related adverse effects were limited to the central nervous system.
  • No deaths were attributable to treatment.
  • Drug-related Grade 3 or 4 toxicity was seen in 39% of patients in all dose groups and 22% of patients at the maximum tolerated dose of 6 microg/ml x 40 ml.
  • Gadolinium-enhanced magnetic resonance imaging of the brain showed areas of decreased signal intensity within the tumor consistent with tumor necrosis following treatment in many patients.
  • CONCLUSIONS: NBI-3001 appears to have an acceptable safety and toxicity profile when administered intratumorally in patients with recurrent malignant glioma.
  • [MeSH-major] Astrocytoma / drug therapy. Bacterial Toxins / administration & dosage. Exotoxins / administration & dosage. Glioblastoma / drug therapy. Immunotoxins / administration & dosage. Interleukin-4 / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Supratentorial Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Dose-Response Relationship, Drug. Female. Humans. Infusions, Intralesional. Magnetic Resonance Imaging. Male. Middle Aged. Prospective Studies. Stereotaxic Techniques

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14531567.001).
  • [ISSN] 0065-1419
  • [Journal-full-title] Acta neurochirurgica. Supplement
  • [ISO-abbreviation] Acta Neurochir. Suppl.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Bacterial Toxins; 0 / Exotoxins; 0 / Immunotoxins; 0 / interleukin-4-Pseudomonas exotoxin; 207137-56-2 / Interleukin-4
  •  go-up   go-down


22. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol; 2000 Feb;18(4):708-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Little progress has been made in the treatment of adult high-grade gliomas over the last two decades, thus necessitating a search for novel therapeutic strategies.
  • Malignant gliomas are vascular or angiogenic tumors, which leads to the supposition that angiogenesis inhibition may represent a potentially promising strategy in the treatment of these tumors.
  • We present the results of a phase II trial of thalidomide, a putative inhibitor of angiogenesis, in the treatment of adults with previously irradiated, recurrent high-grade gliomas.
  • PATIENTS AND METHODS: Patients with a histologic diagnosis of anaplastic mixed glioma, anaplastic astrocytoma, or glioblastoma multiforme who had radiographic demonstration of tumor progression after standard external-beam radiotherapy with or without chemotherapy were eligible.
  • Patients were initially treated with thalidomide 800 mg/d with increases in dose by 200 mg/d every 2 weeks until a final daily dose of 1,200 mg was achieved.
  • One patient developed a grade 2 peripheral neuropathy after treatment with thalidomide for nearly a year.
  • Eight patients were alive more than 1 year after starting thalidomide, although almost all with tumor progression.
  • Changes in serum levels of basic fibroblastic growth factor (bFGF) were correlated with time to tumor progression and overall survival.
  • CONCLUSION: Thalidomide is a generally well-tolerated drug that may have antitumor activity in a minority of patients with recurrent high-grade gliomas.
  • Future studies will better define the usefulness of thalidomide in newly diagnosed patients with malignant gliomas and in combination with radiotherapy and chemotherapy.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Supratentorial Neoplasms / drug therapy. Thalidomide / therapeutic use
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Combined Modality Therapy. Constipation / chemically induced. Disease Progression. Female. Fibroblast Growth Factor 2 / blood. Follow-Up Studies. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Humans. Hypnotics and Sedatives / adverse effects. Male. Middle Aged. Peripheral Nervous System Diseases / chemically induced. Remission Induction. Survival Rate

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2000 Oct 1;18(19):3453 [11013292.001]
  • (PMID = 10673511.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Biomarkers, Tumor; 0 / Hypnotics and Sedatives; 103107-01-3 / Fibroblast Growth Factor 2; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


23. Weber F, Asher A, Bucholz R, Berger M, Prados M, Chang S, Bruce J, Hall W, Rainov NG, Westphal M, Warnick RE, Rand RW, Floeth F, Rommel F, Pan H, Hingorani VN, Puri RK: Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol; 2003 Aug-Sep;64(1-2):125-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma.
  • PURPOSE: This was an open-label, dose-escalation trial of intratumoral administration of IL-4 Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma.
  • PATIENTS AND METHODS: A total of 31 patients with histologically verified supratentorial grades 3 and 4 astrocytoma were studied.
  • RESULTS: No drug-related systemic toxicity, as evident by lack of hematological or serum chemical changes, was apparent in any patients; treatment-related adverse effects were limited to the central nervous system.
  • No deaths were attributable to treatment.
  • Drug-related grade 3 or 4 toxicity was seen in 39% of patients in all dose groups and 22% of patients at the maximum tolerated dose of 6 microg/ml x 40 ml.
  • Gadolinium-enhanced magnetic resonance imaging of the brain showed areas of decreased signal intensity within the tumor consistent with tumor necrosis following treatment in many patients.
  • CONCLUSIONS: NBI-3001 appears to have an acceptable safety and toxicity profile when administered intratumorally in patients with recurrent malignant glioma.
  • [MeSH-major] Astrocytoma / drug therapy. Bacterial Toxins / therapeutic use. Cerebellar Neoplasms / drug therapy. Exotoxins / therapeutic use. Glioblastoma / drug therapy. Interleukin-4 / therapeutic use. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies / analysis. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Safety. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2157-65 [10873064.001]
  • [Cites] Oncol Rep. 2000 Jul-Aug;7(4):899-904 [10854567.001]
  • [Cites] J Neurosurg. 1994 Mar;80(3):520-6 [8113865.001]
  • [Cites] Glia. 1995 Nov;15(3):244-56 [8586461.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2076-80 [8134351.001]
  • [Cites] Breast Cancer Res Treat. 1994;32(1):97-103 [7819590.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Cell Immunol. 1996 Jul 10;171(1):80-6 [8660841.001]
  • [Cites] Br J Cancer. 1997;75(6):822-8 [9062402.001]
  • [Cites] Int J Cancer. 2001 Apr 15;92(2):168-75 [11291041.001]
  • [Cites] Int J Cancer. 1994 Aug 15;58(4):574-81 [8056454.001]
  • [Cites] Nat Med. 1997 Dec;3(12):1362-8 [9396606.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3357-63 [7614471.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1168-72 [10728667.001]
  • [Cites] J Neurosurg. 1995 Jun;82(6):1021-9 [7539062.001]
  • [Cites] Cancer Res. 1996 Dec 15;56(24):5631-7 [8971168.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):14-25 [11554386.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):326-34 [10690507.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):6889-93 [8041715.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):316-9 [9927039.001]
  • [Cites] Cytokine. 2000 Nov;12(11):1656-61 [11052816.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1103-9 [11861389.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3649-53 [9721874.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8058-61 [11719427.001]
  • (PMID = 12952293.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Bacterial Toxins; 0 / Exotoxins; 0 / interleukin-4-Pseudomonas exotoxin; 207137-56-2 / Interleukin-4
  •  go-up   go-down






Advertisement